PGP and cancer: In 2024, Braconi et al. proposed a new series of piperazine derivatives bearing a coumarin scaffold with the aim of obtaining dual inhibitors of P-glycoprotein (P-gp), an ABC transporter [30], and hCA XII to synergistically overcome P-gp-mediated multidrug resistance (MDR) in cancer cells [31].